$21.90
-0.31[-1.40%]
At close: Apr 26
$21.90
0[0.00%]
After Hours: 7:33PM EDT
Corcept Therapeutics
(NASDAQ:CORT)Latest News for Corcept Therapeutics Stock (NASDAQ:CORT)
Corcept Therapeutics Stock (NASDAQ: CORT)
Categories: All
Tuesday, April 23, 2024
Monday, April 22, 2024
- Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This QuarterVandana Singh - 5 days ago
- Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory EndpointsBenzinga Newsdesk - 5 days ago
- Corcept Announces Results From Open-Label Portion Of Pivotal Phase 3 GRACE Trial In Patients With Cushing's SyndromeBenzinga Newsdesk - 5 days ago
Monday, April 15, 2024
Monday, April 08, 2024
Monday, April 01, 2024
Friday, February 16, 2024
Thursday, February 15, 2024
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial; Of The First 700 Patients Enrolled In Catalyst, 24% Were Identified As Having HypercortisolismBenzinga Newsdesk - Feb 15, 2024, 4:25PM
- Recap: Corcept Therapeutics Q4 EarningsBenzinga Insights - Feb 15, 2024, 4:15PM
- Corcept Therapeutics Reiterated FY24 Revenue $600M-$630M Vs $531.574M Est.Benzinga Newsdesk - Feb 15, 2024, 4:14PM
- Corcept Therapeutics Q4 2023 GAAP EPS $0.28 Beats $0.26 Estimate, Sales $135.40M Beat $129.30M EstimateBenzinga Newsdesk - Feb 15, 2024, 4:09PM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
- Earnings Preview: Corcept TherapeuticsBenzinga Insights - Feb 14, 2024, 11:01AM
- Significant Move: Gary Charles Robb Invests $105K In Corcept Therapeutics Stock OptionsBenzinga Insights - Feb 14, 2024, 10:02AM
- A Noteworthy Decision By Atabak Mokari As Acquires $105K In Corcept Therapeutics Stock OptionsBenzinga Insights - Feb 14, 2024, 10:02AM
- Hazel Hunt Sees Potential Growth And Acquires $105K In Corcept Therapeutics Stock OptionsBenzinga Insights - Feb 14, 2024, 10:01AM
- Joseph Douglas Lyon Enhances Portfolio With Corcept Therapeutics Stock Options: $79K AcquiredBenzinga Insights - Feb 14, 2024, 10:01AM
- William Guyer Expands Holdings With Corcept Therapeutics Stock OptionsBenzinga Insights - Feb 14, 2024, 10:01AM
- Joseph K Belanoff Makes A Tactical Move: Adds Corcept Therapeutics Stock Options To PortfolioBenzinga Insights - Feb 14, 2024, 10:01AM
Monday, January 22, 2024
Monday, January 08, 2024
- Corcept Therapeutics shares are trading higher after the company reported preliminary Q4 and full year 2023 revenue results above estimates, issued 2024 revenue guidance above estimates and announced a $200 million stock repurchase program.Benzinga Newsdesk - Jan 8, 2024, 9:16AM
- Corcept Therapeutics Provides Financial Update And Announces $200M Stock Repurchase Program; Sees Q4 Revenue $135.4M Vs $127.85M Est.; FY23 Revenue $482.4M Vs $474.82M Est.; FY24 Revenue $600M–$630M Vs $513.85M Est.Benzinga Newsdesk - Jan 8, 2024, 8:28AM
Tuesday, January 02, 2024
- Crude Oil Down 2%; Tesla Deliveries Top EstimatesAvi Kapoor - Jan 2, 2024, 2:17PM
- Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Jan 2, 2024, 1:35PM
- HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $28Benzinga Newsdesk - Jan 2, 2024, 1:21PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Jan 2, 2024, 12:31PM
- Dow Turns Higher; Anavex Life Sciences Shares PlungeAvi Kapoor - Jan 2, 2024, 12:15PM
- Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On TuesdayAvi Kapoor - Jan 2, 2024, 11:47AM
- Corcept Therapeutics shares are trading lower after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800.Benzinga Newsdesk - Jan 2, 2024, 8:42AM
- Corcept Therapeutics Announces Court Issued Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims Of Corcept's US PatentsBenzinga Newsdesk - Jan 2, 2024, 8:12AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Jan 2, 2024, 8:05AM
- Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in JanuaryAvi Kapoor - Jan 2, 2024, 7:06AM
Monday, January 01, 2024
Wednesday, December 13, 2023
- Corcept Therapeutics shares are trading higher after Canaccord Genuity maintained the stock with a Buy rating and raised its price target from $37 to $38.Benzinga Newsdesk - Dec 13, 2023, 2:01PM
- Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38Benzinga Newsdesk - Dec 13, 2023, 11:48AM
Thursday, December 07, 2023
Monday, November 06, 2023
Thursday, November 02, 2023
Wednesday, November 01, 2023
- Corcept Therapeutics Increases FY23 Revenue From $455M-$470M To $470M-$480M Vs $465.62M Est.Benzinga Newsdesk - Nov 1, 2023, 5:22PM
- Corcept Therapeutics Q3 2023 EPS $0.28 Down From $0.30 YoY, Revenue $123.6M Beats $119.678M EstimateBenzinga Newsdesk - Nov 1, 2023, 4:28PM
- Corcept Appoints Monica Tellado As President, Emerging MarketsBenzinga Newsdesk - Nov 1, 2023, 8:17AM
- Earnings Scheduled For November 1, 2023Benzinga Insights - Nov 1, 2023, 7:19AM